FDA 483 - WuXi Advanced Therapies

Wuxi Advanced Therapies, a drug product manufacturer in Philadelphia, was cited for significant deficiencies in its aseptic operator qualification program. The inspection revealed issues including inadequate aseptic technique, insufficient training, lack of supervisory oversight, and failure to follow standard operating procedures and batch record instructions during aseptic operations. These conditions indicate a potential risk to product quality and sterility.